Skip to main content

Published locations for ICYMI: Elotuzumab reduces progression risk in lenalidomide-refractory multiple myeloma

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. ICYMI: Elotuzumab reduces progression risk in lenalidomide-refractory multiple myeloma

User login

  • Reset your password
  • /content/icymi-elotuzumab-reduces-progression-risk-lenalidomide-refractory-multiple-myeloma
  • /hematologynews/article/183910/multiple-myeloma/icymi-elotuzumab-reduces-progression-risk
  • /oncologypractice/article/183910/multiple-myeloma/icymi-elotuzumab-reduces-progression-risk
  • /hematology-oncology/article/183910/multiple-myeloma/icymi-elotuzumab-reduces-progression-risk